PET/CT with F18-FDG initial staging in patients with esophageal cancer
Keywords:
Esophageal cancer, Metastasis, Positron-emission tomographyAbstract
Esophageal cancer usually manifests as an advanced disease, in the staging process the most important advantage of the positron- emission tomography (18-F-FDG PET/CT) lies in its ability to detect distant metastases. This offers changes in therapy in approximately a third of patients, who are not eligible for surgical Management.
Author Biography
Alejandro Martí Samper, Instituto Nacional de Cancerología
Servicio de Medicina Nuclear, Instituto Nacional de Cancerología, Bogotá, Colombia
References
Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-52.
https://doi.org/10.1056/NEJMra035010
Conti PS, Kaushik A, editores. PET-CT: A Case-Based Approach. New York: Springer; 2016. p. 322.
https://doi.org/10.1007/978-1-4419-5811-2
Skehan SJ, Brown AL, Thompson M, Young JE, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics. 2000;20:713-23.
https://doi.org/10.1148/radiographics.20.3.g00ma04713
van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Esophageal ca-neoadjuvant chemo-RT/Dutch data-CROSS trial (Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
https://doi.org/10.1056/NEJMoa1112088
Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232-48.
https://doi.org/10.3322/caac.21185
Kwee RM, Marcus C, Sheikhbahaei S, Subramaniam RM. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. PET Clin. 2015;10:197-205.
https://doi.org/10.1016/j.cpet.2014.12.003
Shi W, Wang W, Wang J, Cheng H, Huo X. Meta-analysis of 18FDG PET-CT for nodal staging in patients with esophageal cancer. Surg Oncol. 2013;22:112-6.
https://doi.org/10.1016/j.suronc.2013.02.003
Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med. 2012;53:864-71.
https://doi.org/10.2967/jnumed.111.101568
Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czernin J. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go. Q J Nucl Med Mol imaging. 2011;55:620-32.
Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg. 2000;120:1085-92.
https://doi.org/10.1067/mtc.2000.110464
Pifarré-Montaner P, Fernández-León A, de Juan R, del Ama- Salvador ME, Galán M, Gámez-Cenzano, et al. Impact of (18)F-FDG PET/CT on the therapeutic management in the initial staging of the esophageal cancer. Rev Esp Med Nucl. 2009;28:101-5.
https://doi.org/10.1016/S0212-6982(09)71351-5
Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med. 2000;25:882-7.
https://doi.org/10.1097/00003072-200011000-00005
Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005;103:148-56.
https://doi.org/10.1002/cncr.20724
van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98:547-57.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
